Eli Lilly | LLY - Stock


Eli Lilly reported $14.53B in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
AbbVie USD 5.05B 98M Mar/2026
Abbott USD 6.99B 501M Mar/2026
ALKERMES USD 336.7M 140.08M Mar/2026
Amgen USD 6.19B 39M Mar/2026
AstraZeneca USD 6.57B 13M Mar/2026
Baxter International USD 2.32B 84M Mar/2026
Biogen USD 1.95B 219.1M Mar/2026
Bristol-Myers Squibb USD 2.76B 66M Mar/2026
Coherus Biosciences USD 3.17M 1.12M Dec/2025
Drreddys Laboratories INR 76.53B 2.48B Mar/2026
Eli Lilly USD 14.53B 785M Mar/2026
Gilead Sciences USD 1.91B 140M Mar/2026
GlaxoSmithKline GBP 6.16B 233M Mar/2026
Glaxosmithkline GBP 6.16B 39M Mar/2026
J&J USD 14.58B 392M Mar/2026
Medtronic USD 6.31B 153M Dec/2025
Merck USD 6.48B 179M Mar/2026
Neurocrine Biosciences USD 64.5M 4.5M Mar/2026
Novartis USD 6.29B 17M Mar/2026
Novartis USD 6.29B 135M Mar/2026
Novo Nordisk DKK 45.65B 21.26B Jun/2025
Perrigo USD 1.12B 27.6M Mar/2026
Pfizer USD 10.67B 13M Mar/2026
Phibro Animal Health USD 539.7M 22.35M Mar/2026
Prestige Brands USD 159.13M 4.46M Mar/2026
Regeneron Pharmaceuticals USD 3.1B 97.2M Mar/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sanofi EUR 22.69B 1.81B Dec/2025
Sanofi EUR 23.5B 812M Mar/2026
United Therapeutics USD 178.3M 4.8M Mar/2026
Zoetis USD 2.55B 120M Mar/2026